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Articles
Determinants of ovarian function after response-adapted 
therapy in patients with advanced Hodgkin’s lymphoma 
(RATHL): a secondary analysis of a randomised phase 3 trial
Richard A Anderson, Rachel Remedios, Amy A Kirkwood, Pip Patrick, Linsey Stevens, Laura Clifton-Hadley, Tom Roberts, Chris Hatton, 
Nagesh Kalakonda, Don W Milligan, Pam McKay, Clare Rowntree, Fiona M Scott, Peter W M Johnson
Summary
Background Adverse effects on reproductive function are a key concern in young women treated with chemotherapy 
for advanced Hodgkin’s lymphoma. We aimed to identify risk factors for the extent of ovarian damage in women with 
Hodgkin’s lymphoma treated with different chemotherapy regimens to inform accurate advice on options for fertility 
preservation.
Methods We recruited female participants from the randomised phase 3 RATHL trial, aged 18–45 years, based on 
availability of participants at recruiting sites in the UK. The RATHL trial key inclusion criteria were histologically 
confirmed classic Hodgkin’s lymphoma, stage IIB–IV or IIA with adverse features (bulky disease or more than two 
sites of involvement), no previous treatments, and a performance status of 0–3. As part of RATHL, participants were 
treated with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or AVD followed by an 
interim PET-CT scan. Participants who had negative interim scans (PET score of 1 to 3 according to the Lugano 
classification) were randomly assigned (1:1) by use of minimisation, stratified by interim PET score and study centre, 
to continue ABVD or AVD for four more cycles. Participants with positive scans (PET score of 4 or 5) were escalated 
to treatment with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone 
(BEACOPP-14 or escalated BEACOPP) for four cycles. For the protocol-driven prospective cohort substudy, ovarian 
function was assessed before treatment, during chemotherapy, and then annually for 3 years by use of serum 
antimüllerian hormone and follicle-stimulating hormone measurements. The RATHL study is registered with 
ClinicalTrials.gov, number NCT00678327.
Findings Between Dec 13, 2010, and Dec 19, 2012, 67 eligible participants were recruited for this prospective cohort 
study; 57 had received ABVD or AVD (ABVD-AVD group) and ten BEACOPP-14 or escalated BEACOPP (BEACOPP 
group). Follow-up was fixed at 3 years. Antimüllerian hormone concentrations decreased during both chemotherapy 
regimens. At 1 year after chemotherapy, antimüllerian hormone concentrations recovered to a median of 10·5 pmol/L 
(IQR 4·3–17·3) in the ABVD-AVD group, but little recovery was seen after BEACOPP (median 0·11 pmol/L [0·07–0·20]). 
Age also affected the extent of ovarian function recovery, with antimüllerian hormone recovery in participants aged 
35 years or older in the ABVD-AVD group to 37% (SD 10) of their before treatment concentrations, compared with full 
recovery to 127% (SD 12) in those younger than 35 years (p<0·0001). Follicle-stimulating hormone recovery to less than 
25 IU/L occurred for 95% of women younger than 35 years in the ABVD-AVD group by 2 years and was also dependent 
on age (hazard ratio 0·49, 95% CI 0·37–0·65; p<0·0001).
Interpretation Reduced recovery of ovarian function observed in women older than 35 years treated with ABVD or 
AVD compared with younger women indicates that treatment could reduce their reproductive lifespan and supports 
discussion of fertility preservation before treatment. Women treated with BEACOPP should be informed of its 
potential high gonadotoxicity. These findings warrant further investigation in large, prospective studies with fertility 
and reproductive lifespan as outcomes.
Funding Medical Research Foundation and Cancer Research UK.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY-NC-ND 
4.0 license.
Introduction
Hodgkin’s lymphoma is predominantly a cancer of young 
adult life, occurring at a median age of 35 years. Systemic 
treatment for this condition has evolved from 
chemotherapy regimens based on alkylating agents, which 
had a high risk of infertility and premature ovarian 
insufficiency in women, to treatment with doxorubicin, 
bleomycin, vinblastine, and dacarbazine (ABVD), which is 
the current treatment of choice for many adult patients 
with Hodgkin’s lymphoma. ABVD results in a disease-free 
survival of 75%,1 and with less gonadotoxicity than previous 
treatments.2 Increasing evidence supports that treatment 
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intensification could benefit patients who are at higher 
risk of relapse, and some clinicians advocate treat-
ment with bleomycin, etoposide, doxorubicin, cyclophos-
phamide, vincristine, procarbazine, and prednisolone 
(BEACOPP) for patients with advanced stage or high-risk 
early stage disease. However, female gonadal toxicity is 
high with dose-escalated BEACOPP resulting in amenor-
rhoea (a surrogate marker of pre mature ovarian insuf-
ficiency) in about 95% of patients older than 30 years.3
Analysis of the effects of cancer therapies on the ovaries 
requires consideration of both the degree of loss of 
ovarian function during chemotherapy and changes in 
ovarian function thereafter. The degree of loss of the 
primordial follicle pool (the ovarian reserve) during 
chemotherapy is the most important effect since it 
determines the potential for any recovery of ovarian 
function and fertility, and subsequent age at menopause, 
although the degree of loss cannot be assessed in vivo. 
Additional effects of chemotherapy might be seen on the 
non-follicular components of the ovary, including the 
stroma and vasculature.4 Few prospective analyses have 
been done of ovarian function from the time of diagnosis 
and before chemotherapy.5–9 Most larger studies use 
amenor rhoea to indicate loss of ovarian function,3 and 
so are unable to differentiate between women who 
have largely intact remaining ovarian function and 
those who have lost most of their ovarian reserve and 
will soon become menopausal and infertile.2,10 
Although measurement of follicle-stimulating hormone 
concentration is central to the diagnosis of premature 
ovarian insufficiency, the hormone has substantial 
variation during the menstrual cycle, complicating its use 
to measure ovarian reserve in women with ovarian 
activity.11 Analysis of concentrations of serum antimül-
lerian hormone as an indirect biomarker of the ovarian 
reserve has become increasingly valuable for women with 
ovarian activity.12 Antimüllerian hormone concen trations 
decrease during chemotherapy in girls and women, with 
variable recovery after treatment reflecting the 
gonadotoxicity of each regimen.5–8 In the past 5 years, 
refinements in assay methods have improved their 
sensitivity, and thus their ability to detect low circulating 
concentrations of antimüllerian hormone in women after 
chemotherapy, which were previously unde tectable.13,14 
How the pretreatment ovarian reserve and the patient’s 
age influence recovery of ovarian function after chemo-
therapy is unclear, with most data derived from women 
who have been treated for breast cancer.5,9,15,16 In this study, 
we aimed to determine the effect of response-adapted 
chemotherapy regimens on ovarian function in adult 
women with Hodgkin’s lymphoma, since they are both a 
younger population and often treated with less 
gonadotoxic drugs than women with breast cancer.
Methods
Study design and participants
In this prospective cohort study, participants were 
recruited from the RATHL trial, which used PET-CT 
Research in context
Evidence before this study
Chemotherapy regimens are associated with toxic effects on 
human ovaries, manifesting as premature ovarian insufficiency, 
infertility, and reduced reproductive lifespan. Therefore, 
accurate assessment of the ovarian toxicity of widely used 
chemotherapy regimens is needed. We searched PubMed for 
articles published in English between inception and 
March 12, 2018, using the terms “ovary”, “ovarian reserve”, 
“chemotherapy”, and “cancer”. We found little data from 
prospective studies that used current biomarkers of ovarian 
function. Both age and ovarian reserves before treatment are 
predictive of ovarian recovery after chemotherapy with some 
regimens, but their importance is unknown for treatments for 
patients with Hodgkin’s lymphoma.
Added value of this study
We found that changes in antimüllerian hormone 
concentration could distinguish between the effects of 
treatment on ovarian function with doxorubicin, bleomycin, 
vinblastine, and dacarbazine (ABVD) or AVD, and bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, 
procarbazine, and prednisolone (BEACOPP) in patients with 
advanced Hodgkin’s lymphoma, particularly from 3 years of 
follow-up after chemotherapy. Treatment with ABVD or AVD 
was confirmed to have little gonadotoxcity in female patients 
with Hodgkin’s lymphoma who were younger than 35 years at 
diagnosis; however, in older patients (≥35 years) recovery of 
ovarian function was affected by age. We found that among 
older women baseline concentrations of antimüllerian 
hormone did not affect recovery, so reduced hormone recovery 
in older women was not due to the age-related decline in 
ovarian reserve. Little recovery in ovarian function was seen 
after treatment with BEACOPP in women of all ages, although 
a similar number of pregnancies was observed in the two 
treatment groups. Due to the small size of the cohorts analysed, 
these results warrant further confirmation.
Implication of all the available evidence
The absence of detectable ovarian damage after treatment with 
ABVD or AVD in younger women with Hodgkin’s lymphoma is 
reassuring, although longer follow-up is needed in future 
studies for a full assessment of potential reproductive effects. 
Antimüllerian hormone is not a predictor of short-term fertility. 
The finding of reduced ovarian recovery in older women with 
Hodgkin’s lymphoma treated with chemotherapy indicates that 
age-specific discussions and consideration of fertility 
preservation procedures should be considered before 
treatment. These considerations are of growing importance 
given the increasing age at which women are having children in 
developed countries.
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to guide response-adapted chemotherapy, for patients 
with advanced Hodgkin’s lymphoma (appendix p 1).17 
Recruitment for RATHL was open in hospitals across the 
UK, Italy, Norway, Sweden, Denmark, Australia, and 
New Zealand from Aug 29, 2008, to Dec 21, 2012. RATHL 
inclusion criteria were histologically confirmed classic 
Hodgkin’s lymphoma according to the WHO classifi-
cation; age 18 years or older; stage IIB–IV or IIA with 
adverse features (such as bulky disease or more than two 
sites of involvement); no previous treatment with chemo-
therapy, radiotherapy, or investigational treat ments for 
Hodgkin’s lymphoma; performance status 0–3 (according 
to WHO criteria); adequate bone marrow function; 
creatinine less than 150% of the upper limit of normal 
(ULN); bilirubin concentration less than two times ULN; 
aminotransferase concentration less than 2·5 times 
ULN; and life expectancy of more than 3 months. The 
full eligibility criteria for the RATHL trial are available in 
the protocol.
For this prospective cohort substudy, women and aged 
18–45 years (ie, premenopausal) were actively recruited 
from RATHL sites in the UK (appendix pp 3–5). The 
protocol for the substudy is available online.
This cohort substudy received centralised ethical 
committee approval that covered all sites (National 
Research Ethics Service, Southampton and South West 
Hampshire) and all participants gave written informed 
consent.
Procedures
In the RATHL study, after initial staging and a baseline 
PET-CT scan, participants were treated with two cycles of 
ABVD, intravenously, on days 1 and 15 of a 28 days cycle 
followed by an interim PET-CT scan (doses and schedule 
in the appendix [p 2]). Participants who had negative 
interim scans by central review (PET score of 1 to 3 per 
Lugano criteria) were randomly assigned (1:1) by the 
Cancer Research UK and University College London 
Cancer Trials Centre using minimisation, with 
stratification according to PET score (1, 2, or 3) and 
centre, to continue ABVD (intravenously, days 1 and 15) 
or to receive doxorubicin, vinblastine, and dacarbazine 
(AVD; intravenously, days 1 and 15) for four more cycles. 
Since randomisation was done centrally, concealment of 
assignment was not an issue. Participants with positive 
scans (PET score of 4 or 5) were escalated to either 
BEACOPP-14 for six cycles of 14 days or escalated 
BEACOPP for four cycles (doses and schedule in the 
appendix [p 2]). Neither patients nor study staff were 
masked to allocation.
Ovarian function was assessed by use of serum 
concentrations of antimüllerian hormone in participants 
enrolled into this substudy and follicle-stimulating 
hormone concen trations from all eligible participants 
(women and aged 18–45 years) from the RATHL trial. 
Luteinising hormone and oestradiol measurements were 
also taken. Oestradiol measurements are necessary for 
the identification of women with premature ovarian 
insufficiency.11
During the RATHL trial, blood samples were taken 
before any treatment, after two cycles of initial ABVD 
treatment, at the end of chemotherapy, and at 1, 2, and 
3 years after chemotherapy. Samples taken after 
participants showed disease progression and required 
additional treatment were excluded from both analyses 
reported here. Sampling was not timed by the partici-
pant’s stage of menstrual cycle. Follicle-stimulating 
hormone measure ments were done locally as part of the 
RATHL trial; additional samples from participants 
enrolled in this substudy were taken to measure 
antimüllerian hormone, follicle-stimulating hormone, 
luteinising hormone, and oestradiol concen trations by 
use of Roche Elecsys assays (automated cobas e 411 
For RATHL protocol and 
substudy protocol see http://
www.ctc.ucl.ac.uk/TrialDetails.
aspx?Trial=66&TherA=4
1214 participants registered for RATHL
415 eligible for RATHL subanalysis
 115 recruited at ovarian substudy sites 
 74 registered for ovarian substudy
391 evaluable for RATHL subanalysis
 321 after treatment FSH analysis
 282 ABVD-AVD group (142 received 
 ABVD and 140 received AVD)
 39 BEACOPP (19 received 
 BEACOPP-14 and 20 escalated 
 BEACOPP)
 67 evaluable for ovarian function
 substudy
 57 ABVD-AVD group (24 received 
 ABVD and 33 AVD)
 10 BEACOPP (4 received BEACOPP-14 
 and 6 escalated BEACOPP)
94 excluded from subanalysis or FSH 
 recovery analysis
 24 off study before or at the second 
 PET-CT scan
 7 registered for the substudy
 70 excluded from FSH recovery analysis
 29 baseline FSH measurement 
 missing
 6 baseline FSH >25 IU/L
 35 no after treatment FSH data 
 available
799 not eligible for substudy analysis
 12 ineligible for RATHL
 5 misdiagnosed
 3 did not have advanced-stage 
 disease
 1 thyroid cancer detected on PET
 3 not fit enough for treatment
 787 male or aged 45 years or older
Figure 1: Study profile
RATHL trial and ovarian function substudy participants who contributed to 
analysis. ABVD=doxorubicin, bleomycin, vinblastine, and dacarbazine. 
AVD=doxorubicin, vinblastine, and dacarbazine. BEACOPP=bleomycin, etoposide, 
doxorubicin, cyclophosphamide, vincristine, procarbazine, 
and prednisolone. FSH=follicile-stimulating hormone.
See Online for appendix
Articles
4 www.thelancet.com/oncology   Published online September 13, 2018   http://dx.doi.org/10.1016/S1470-2045(18)30500-X
analyser, Roche, Burgess Hill, UK). The substudy samples 
were sent by post to a central laboratory (MRC Centre for 
Reproductive Health, Edinburgh), where the serum was 
stored at –20°C until analysis. The antimüllerian hormone 
assay has a limit of detection of 0·07 pmol/L, and for all 
assays the interassay and intra-assay coefficients of 
variation were below 5%. A follicle-stimulating hormone 
threshold of more than 25 IU/L indicated probable 
premature ovarian insuffi ciency.11
After recovery from chemotherapy, antimüllerian 
hormone was additionally analysed in association with 
predictors from before treatment, specifically age and 
antimüllerian hormone concentration. Antimüllerian 
hormone recovery was calculated at 2 years after 
chemotherapy to allow full recovery of ovarian function 
but minimise any age-related changes. The study was not 
designed to assess fertility, and menstrual bleeding was 
not recorded since it does not help to distinguish between 
women with normal ovarian function and those with 
very depleted ovarian reserves.
Data on previous pregnancy or use of hormonal 
contraceptives were only collected from participants 
enrolled in the ovarian function substudy. Decisions 
regarding fertility preservation procedures were between 
the participant and the local centre, and were not recorded 
as part of the study.
Outcomes
The primary outcome of this study, specified as an 
exploratory outcome in the RATHL trial, was assessment 
of gonadal function. The prespecified outcomes in this 
substudy were analysis of acute toxic effects of each 
treatment regimen on the ovaries, and ovarian function 
after treatment (including progression to ovarian failure 
and recovery of ovarian function). Other prespecified 
outcomes were the association between fertility after 
treatment and ovarian function before treatment, degree 
of acute ovarian toxic effects, which will be reported 
separately.
Statistical analysis
As a secondary analysis of the RATHL trial, the prespecified 
exploratory analyses presented here are not powered; we 
aimed to recruit as many patients as possible while the 
RATHL trial was open. We hypo thesised that antimüllerian 
hormone concentrations could show differences between 
the gonadotoxicity of the chemo therapy regimens in the 
RATHL trial, both during and after treatment, and that 
concentrations of antimüllerian hormone before treatment 
would be predictive of recovery of ovarian function after 
treatment. We analysed antimüllerian hormone and 
follicle-stimulating hormone concentrations in the ovarian 
subgroup after log transformation using ANOVA with 
Bonferroni’s multiple comparisons test for changes during 
treatment and recovery. We calculated Pearson correlation 
coefficients and used multiple linear regression without 
trans formation to analyse age and before treatment 
concentration of antimüllerian hormone against percen-
tage hormone recovery (calculated as [concentration at 
2 years÷concentration before treatment] x 100) and against 
concentration at 2 years. We used the Mann-Whitney 
U test to compare hormone concentrations between the 
treatment groups. We analysed proportions of participants 
using Fisher’s exact test to determine the number of 
women who had a pregnancy after chemotherapy. We 
measured follicle-stimulating hormone recovery using 
Cox regression and Kaplan-Meier survival analysis. We 
measured time to recovery (follicle-stimulating hormone 
concentration of ≤25 IU/L) from the end of treatment until 
the first follicle-stimulating hormone measurement of 
25 IU/L or less, or a reported pregnancy (whichever came 
first). Patients with follicle-stimulating hormone 
concentrations of more than 25 IU/L at baseline were 
excluded, and patients who had neither event were 
censored at the last reported follicle-stimulating hormone 
measurement. Any measurements recorded after disease 
progression were excluded from all analyses because 
patients would have been exposed to further treatment at 
this point. We tested the assumption of proportional 
Ovarian function 
substudy cohorts
RATHL trial cohorts
ABVD-AVD 
group 
(n=57)
BEACOPP 
group 
(n=10)
ABVD 
group 
(n=165)
AVD group 
(n=171)
BEACOPP-14 
group (n=27)
Escalated 
BEACOPP 
group 
(n=28)
Age, years 26 (18–44) 31 (19–43) 27 (18–44) 28 (18–44) 24 (18–44) 35 (18–43)
International 
prognostic index of 
3 or more
4 (7%) 4 (40%) 33 (20%) 24 (14%) 9 (33%) 7 (25%)
WHO performance status
0 47 (82%) 7 (70%) 123 (75%) 143 (84%) 20 (74%) 20 (74%)*
1 9 (16%) 2 (20%) 34 (21%) 26 (15%) 7 (26%) 6 (22%)*
2 1 (2%) 1 (10%) 4 (2%) 2 (1%) 0 1 (4%)
3 0 0 4 (2%) 0 0 0
Stage 4 (2%)
II 34 (60%) 3 (30%) 90 (55%) 86 (50%) 14 (52%) 11 (39%)
III 9 (16%) 1 (10%) 37 (22%) 46 (27%) 2 (7%) 7 (25%)
IV 14 (25%) 6 (60%) 38 (23%) 39 (23%) 11 (41%) 10 (36%)
Previous pregnancy 16 (28%) 7 (70%) ·· ·· ·· ··
Hormonal 
contraception at 
baseline
17 (30%) 3 (30%) ·· ·· ·· ··
Baseline 
antimüllerian 
hormone, pmol/L
9·8 
(5·9–18·1)
6·8 
(2·2–12·8)
·· ·· ·· ··
Baseline 
follicle-stimulating 
hormone 
concertation, IU/L
4·6 
(0·3–12)
5·7 
(1·9–21·8)
4·4 
(0·1–48·7)
4·7 
(0·1–50·7)
5·7 
(0·3 –26·5)
3·6 
(0·1 –35·7)
Data are median (range) or n (%) unless otherwise stated. RATHL trial cohort data are for women younger than 45 years 
included in this study. ABVD=doxorubicin, bleomycin, vinblastine, and dacarbazine. AVD=doxorubicin, vinblastine, 
and dacarbazine. BEACOPP= bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, 
and prednisolone. *One patient in this group had a missing performance status.
Table: Baseline characteristics
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hazards using Schoenfeld residuals, and when it did not 
hold we used restricted mean survival times with a 3 year 
cutoff. All p values are two-sided and a p value of less than 
0·05 was considered statistically significant.
Data analyses were done in STATA (version 15.1) and 
Graphpad Prism 7. The RATHL trial is registered with 
ClinicalTrials.gov, number NCT00678327.
Role of the funding source
The funder of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. RAA, AAK, and PWMJ had access 
to the raw data. The corresponding author had final 
responsibility for the decision to submit for publication.
Results
Between Dec 13, 2010, and Dec 19, 2012, participants 
from the RATHL trial were recruited for this ovarian 
function substudy (figure 1; appendix p 3). 115 (9%) of 
1214 participants in the RATHL trial were eligible for the 
substudy, of whom 74 (69%) registered. Seven (10%) of 
74 registered participants were excluded from the substudy 
and the main trial, six for scan protocol deviations, and 
one for psychological reasons, leaving 391 (94%) of 415 
eligible (18–45 years) female RATHL participants, of 
whom 321 (82%) were evaluable for follicle-stimulating 
hormone analyses, and 67 (91%) were evaluable for 
substudy analyses. Of the 67 evaluable participants for the 
substudy analyses, 24 (36%) had been treated with ABVD, 
33 (49%) with AVD, four (6%) with BEACOPP-14, and 
six (9%) with escalated BEACOPP. No difference in 
baseline hormone concentrations were found between 
partici pants treated with ABVD versus AVD, or 
BEACOPP-14 versus escalated BEACOPP (table); thus 
these subgroups were combined as ABVD-AVD (n=57) 
and BEACOPP (n=10), respectively, for subsequent 
analyses. The baseline characteristics of the participants 
who had follicle-stimulating hormone measurements 
from the RATHL trial, and the combined ABVD-AVD and 
BEACOPP subgroups evaluated in this substudy are in 
the table.
For nine participants in the substudy, data at post-
baseline timepoints were not available because of disease 
progression and further treatment (six in the ABVD-AVD 
group, three in the BEACOPP group), and 13 blood 
samples were missing or taken at incorrect timepoints. 
Eight blood samples taken from eight women during 
pregnancy in the ovarian subgroup were excluded from 
analysis.
Antimüllerian hormone concentrations decreased in 
all participants during chemotherapy treatment with 
reciprocal increases in follicle-stimulating hormone 
concentrations (figure 2). In the ABVD-AVD group, 
concentrations of antimüllerian hormone decreased 
from a median of 9·8 pmol/L (IQR 5·9–18·1) before 
treatment to 1·7 pmol/L (IQR 0·4–4·3) at the end of 
treatment (p<0·0001), with a small rise between cycle 
two of initial ABVD treatment and the end of treatment 
(p<0·0001). After chemotherapy in the ABVD-AVD 
group, concentrations of antimüllerian hormone 
increased to 10·5 pmol/L (IQR 4·3–17·3) at 1 year, similar 
to concentrations before treatment, with no change 
at later timepoints (figure 2). Antimüllerian hormone 
was undetectable in two (4%) of 56 participants at the 
end of treatment with follicle-stimulating hormone 
concentration higher than 25 IU/L and low oestradiol 
concentrations indicating premature ovarian insuf-
ficiency. For one of these participants, antimüllerian 
hormone became detectable during recovery, and for the 
other, antimüllerian hormone showed a transient 
recovery at 1 year after treatment, becoming undetectable 
thereafter.
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Figure 2: Ovarian function biomarkers at prespecified timepoints per 
treatment group
(A) Concentrations of antimüllerian hormone and (B) follicle-stimulating 
hormone. All participants included in the substudy were analysed (ABVD-AVD 
group, n=57; BEACOPP group, n=10). Boxes are median and IQR, bars are ranges. 
Panel A is plotted on a log10 scale to clearly show the low concentrations seen in 
the BEACOPP group. ABVD=doxorubicin, bleomycin, vinblastine, and dacarbazine. 
AVD=doxorubicin, vinblastine, and dacarbazine. BEACOPP=bleomycin, etoposide, 
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone.
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In the BEACOPP group, concentrations of anti müllerian 
hormone decreased from a median of 6·8 pmol/L (IQR 
2·2–12·8) before treatment to 0·08 pmol/L (0·07–0·24) at 
the end of treatment (p<0·0001; figure 2). After treatment, 
by contrast with participants in the ABVD-AVD group, 
concentrations of antimüllerian hormone showed very 
little recovery (median 0·11 pmol/L [IQR 0·07–0·20] at 
1 year) and were undetectable in five (71%) of seven 
participants at 3 years (figure 2A).
Follicle-stimulating hormone concentrations had 
generally reciprocal changes compared with concen-
trations of antimüllerian hormone and increased during 
treatment in both groups (figure 2B). Subsequently, 
in the ABVD-AVD group concentrations of follicle-
stimulating hormone decreased to levels similar to before 
treatment at years 1 to 3 after treatment. However, in the 
BEACOPP group, follicle-stimulating hormone con-
centrations did not decrease in the follow-up period. 
Concentrations of luteinising hormone showed the same 
pattern of changes, increasing from before treatment to 
the end of treatment in both groups (both p<0·0001) and 
then recovering after treatment to before-treatment 
concentrations in the ABVD-AVD group, but remaining 
significantly increased after treatment in the BEACOPP 
group (data not shown).
Both antimüllerian hormone concentration 2 years 
after treatment and follicle-stimulating hormone recovery 
data provide evidence of the effect of age on ovarian 
recovery in women treated with ABVD or AVD 
(figures 3 and 4). We saw a correlation between the 
concentration of antimüllerian hormone before treatment 
and at 2 years after treatment (r=0·89; p<0·0001) but not 
with antimüllerian hormone recovery (r=–0·30; p=0·051). 
However, significant and similar negative correlations 
were seen between age and antimüllerian hormone 
concentrations at 2 years (r=–0·40; p=0·0055) and with 
antimüllerian hormone recovery (r=–0·40; p=0·0080). 
This negative effect of age on recovery was supported 
by mean concentrations of antimüllerian hormone at 
recovery, with participants younger than 35 years 
showing complete recovery at 127% (SD 12; median 
10·0 pmol/L [IQR 7·5–21·1] before treatment vs 
13·4 pmol/L [7·1–22·3] at 2 years), whereas concentrations 
in those aged 35 years and older had incomplete recovery 
(37% [SD 10]; ≤35 years, median 5·7 pmol/L [IQR 
2·1–9·7] before treatment vs 1·4 pmol/L [0·2–4·2]) at 
2 years; for comparison of age groups p<0·0001). Analysis 
of antimüllerian hormone concentrations before treat-
ment grouped by whether they were below or above the 
overall median value (9·77 pmol/L [IQR 5·9–18·1]) 
showed that recovery was similar between the two groups 
(below 123% [SD 21] vs above 103% [SD 9]; p=0·85). 
Multiple linear regression analysis also confirmed that 
age had a significant effect on antimüllerian hormone 
recovery (β=–0·43; p=0·004), but that antimüllerian 
hormone con centrations before treatment did not have 
an effect on hormone recovery (β=–0·15, p=0·30). 
Thus, although overall concentrations of antimüllerian 
hormone after treatment seem to recover to before treat-
ment concentrations, the degree of recovery is restricted 
by increasing age.
We also assessed the degree and timecourse of recovery 
of ovarian function, as indicated by normalisation of 
follicle-stimulating hormone concentrations, in the evalu-
able participants from the RATHL trial (figure 4). Follicle-
stimulating hormone measurements after treat ment 
were available from 321 women in the RATHL trial, with 
a median follow-up (censoring at recovery) of 59·3 months 
(IQR 41·9–60·9). Follicle-stimulating hormone concen-
tration recovery to 25 IU/L or lower was seen in 270 (96%) 
of 282 of participants treated with ABVD or AVD, 
compared with 26 (67%) of 39 treated with BEACOPP-14 
or escalated BEACOPP (hazard ratio [HR] 0·37, 95% CI 
0·25–0·56; p=0·0001). The assumption of proportional 
hazards did not hold for this comparison so a better 
estimate is given by the restricted mean survival (recovery) 
times (areas under the curves up to 3 years), which are 
208·9 days for ABVD or AVD and 529·9 days for 
BEACOPP (p<0·0001)—ie, patients treated with ABVD 
or AVD have a mean recovery time of 321·0 days (95% CI 
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Figure 3: Correlations of antimüllerian hormone recovery and before treatment hormone concentrations or 
age for the ABVD-AVD group
Panels show scatter plots of baseline hormone concentration versus concentration at 2 years (A) and versus 
percentage hormone recovery (B), and age versus hormone concentration at 2 years (C) and percentage hormone 
recovery (D). All patients in the ABVD-AVD group of the substudy included. Each dot shows antimüllerian hormone 
concentration or recovery; recovery was calculated for each participant as the concentration at 2 years after 
treatment as a proportion of the concentration before treatment. In the case of missing data, recovery could not 
be calculated. Dotted ine shows linear regression. ABVD=doxorubicin, bleomycin, vinblastine, and dacarbazine. 
AVD=doxorubicin, vinblastine, and dacarbazine. 
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205·7–436·4) less than those treated with BEACOPP. 
Kaplan-Meier estimates for participants treated with 
ABVD or AVD were 75% (95% CI 70–80) 1 year after 
treatment and 93% (89–95) 2 years after treatment, 
whereas the estimates for those treated with BEACOPP 
were 33% (20–52) 1 year after treatment and 69% (52–84) 
2 years after treatment. The relative difference in ovarian 
function (between ABVD or AVD and BEACOPP) did not 
differ when analysed by age (<35 years, HR 0·38, 95% CI 
0·23–0·62; p=0·0001 vs ≥35 years, HR 0·40, 0·19–0·83; 
p=0·011). This pattern was also found when analysed by 
use of restricted mean survival (recovery) times (<35 years, 
154·6 days for ABVD or AVD and 446·5  days for 
BEACOPP [difference: 291·9 days, 95% CI 163·4–420·4; 
p<0·0001] vs ≥35 years, 361·5 days for for ABVD or AVD 
and 663·4 days for BEACOPP [difference 301·9 days, 
95% CI 94·1–509·7; p=0·005]). However, age seemed to 
affect time to recovery among these participants, with a 
smaller proportion of those aged 35 years or older 
showing recovery at both 1 year (41 [50%]) and 2 years 
(64 [79%]) after treatment than those younger than 
35 years did (176 [79%] at 1 year and 211 [95%] at 2 years 
after treatment; HR 0·49, 95% CI 0·37–0·65; p<0·0001). 
Thus, the Kaplan-Meier estimates for follicle-stimulating 
hormone concentration recovery for those younger than 
35 years treated with ABVD or AVD were 83% (95% CI 
77–88) at 1 year and 96% (93–98) at 2 years compared with 
estimates for those aged 35 years and older of 54% (43–66) 
at 1 year and 83% (73–91) at 2 years. The proportions were 
similar between the age groups at 3 years (<35 years 98% 
[95–99] vs ≥35 years 93% [85–97]). We saw no difference 
in follicle-stimulating hormone recovery between partici-
pants treated with escalated BEACOPP or BEACOPP-14 
for all ages (HR 0·72, 95% CI 0·33–1·56).
In the RATHL cohort, 64 (16%) of 391 participants were 
recorded as having 81 pregnancies. Median follow-up for 
the 91 patients was 52 months (IQR 42–64). 57 (17%) 
participants in the ABVD-AVD group had 71 pregnancies 
and seven (13%) participants in the BEACOPP group had 
ten pregnancies. These proportions were not substantially 
different. In the subgroup cohort, antimüllerian hormone 
measurements were available within the follow-up period 
for six women who became pregnant in the ABVD-AVD 
group and two in the BEACOPP group. At 1 year after 
chemotherapy, con centrations of antimüllerian hormone 
ranged from 0·74 pmol/L to 26·9 pmol/L in those who 
became pregnant in the ABVD-AVD group, and were 
0·19 pmol/L and 0·20 pmol/L in those in the BEACOPP 
group. Two women, one in each treatment group, had 
unde tectable antimüllerian hormone, high follicle-
stimulating hormone, and low oestradiol concentrations 
after the recorded pregnancy, consistent with development 
of premature ovarian insufficiency within 3 years of 
chemotherapy treatment.
Adverse event data were reported in detail previously,17 
but they did not include any data on ovarian function or 
fertility. The main study17 found an excess of grade 3–4 
toxic effects from BEACOPP regimens, specifically 
febrile neutropenia and thrombocytopenia. 
Discussion
In this prospective cohort study, we have shown that 
antimüllerian hormone concentrations decrease in 
women with Hodgkin’s lymphoma who are treated with 
ABVD, AVD, or BEACOPP (BEACOPP-14 or escalated 
BEACOPP), and although antimüllerian hormone 
concentrations recover to baseline concentrations after 
treatment with ABVD or AVD, little recovery is seen 
after treatment with BEACOPP. However, we found 
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Figure 4: Recovery of follicle-stimulating hormone concentrations after the 
end of treatment in evaluable patients from the RATHL trial
Kaplan-Meier curves shows recovery of follicle-stimulating hormone 
concentrations per treatment group (A) and by age group (B). Evaluable female 
participants (n=391) were divided by chemotherapy regimen received: ABVD or 
ABVD followed by AVD (ABVD-AVD group), and ABVD followed by BEACOPP-14 
or escalated BEACOPP (BEACOPP group). ABVD=doxorubicin, bleomycin, 
vinblastine, and dacarbazine. AVD=doxorubicin, vinblastine, and dacarbazine. 
BEACOPP=bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, 
procarbazine, and prednisone. HR=hazard ratio. 
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that recovery of ovarian function after treatment with 
ABVD or AVD is dependent on age, with full recovery 
of antimüllerian hormone seen in participants younger 
than 35 years, but not in women aged 35 years or older. 
We found that recovery of follicle-stimulating hormone 
after these two chemotherapy regimens also differed in 
both speed and extent. Follicle-stimulating hormone 
recovery after treatment with ABVD or AVD was slower 
in women aged 35 years or older than in those younger 
than 35 years, and the extent of recovery was much 
lower for those treated with either BEACOPP regimen, 
supporting the increased ovarian toxicity of this drug 
combination. The greater toxicity to other organ 
systems is also reflected in the higher incidence 
of febrile neutropenia and thrombocytopenia with 
BEACOPP.
The potential adverse effect of chemotherapy on 
ovarian function in women with Hodgkin’s lymphoma is 
of major concern, affecting fertility, sexual and bone 
health, and cardiovascular risk. Potential loss of fertility 
is a key concern of young women treated for cancer18 and, 
when appropriate, options for fertility preservation have 
been established; thus, the accurate assessment of the 
effect of different chemotherapy regimens is of 
substantial importance. Assessment of ovarian function 
after treatment via menstrual function and traditional 
biomarkers such as follicle-stimulating hormone are not 
of value in detecting ovarian damage that has resulted in 
incomplete loss of ovarian function. Measurement of 
concentrations of antimüllerian hormone has emerged 
as a reliable biomarker to detect partial loss of ovarian 
function in women after cancer therapy, with the 
additional advantages of showing little variation across 
the menstrual cycle.12 Although most data are from 
women after treatment for breast cancer and childhood 
cancer,5,7,8 we have shown the merit of antimüllerian 
hormone measurements in the assessment of ovarian 
function in adult women with Hodgkin’s lymphoma. 
Specifically, younger women treated with ABVD or AVD 
showed full initial recovery of antimüllerian hormone 
after chemotherapy, consistent with previous data2 that 
indicate that this regimen has little effect on age at 
menopause, but reduced recovery was seen in women 
aged 35 years or older at diagnosis. By contrast, treatment 
with BEACOPP resulted in noticeable and irreversible 
decreases in antimüllerian hormone con centrations, so 
low in many women that the hormone was undetectable 
after treatment even with the highly sensitive assay we 
used. However, the number of participants we analysed 
was small, which should inform interpretation of tests 
of significance. Participants received either escalated 
BEACOPP or BEACOPP-14, a dose-intense version 
that appears to be similarly gonadotoxic to baseline 
BEACOPP.3 Our data support this similarity, although 
the confidence intervals in our estimates were wide.
Antimüllerian hormone concentrations decreased 
quickly during treatment with both regimens, consistent 
with both treatments resulting in loss of the growing 
follicles that are the source of antimüllerian hormone. 
After the initial decrease, a small partial recovery in 
antimüllerian hormone was seen after two cycles in 
women treated with ABVD or AVD during later treatment 
cycles. This finding is consistent with increased activation 
of early follicles during chemo therapy resulting from 
reduced inhibition of growth initiation, which is proposed 
to be part of the mechanism for chemotherapy-induced 
premature ovarian insuffi ciency. This mechanism has 
been shown for high toxicity, cyclophosphamide-based 
regimens,19 but has not previously been identified for low 
toxicity regimens such as ABVD or AVD.
The degree of recovery of antimüllerian hormone after 
treatment with ABVD or AVD in young women could 
indicate a low toxic effect on the non-growing primordial 
follicle pool, which constitutes the true ovarian reserve 
and is the basis for after treatment fertility and the duration 
of the female reproductive lifespan. Under physiological 
conditions, antimüllerian hormone con centrations reflect 
the size of the primordial follicle population, although this 
population size can be perturbed under circumstances 
such as a new diagnosis of lymphoma.20 However, the 
3-year follow-up period in this study is likely to have been 
sufficient for full recovery of ovarian function and therefore 
restoration of physio logical associations between anti-
müllerian hormone and the ovarian reserve. We saw a 
prominent effect of age on recovery, with substantially 
lower recovery in women aged 35 years or older than in 
those younger than 35 years, independent of their 
antimüllerian hormone concentration before treatment. 
This finding indicates an effect either of age alone or of age 
in addition to the effects of ABVD or AVD that result in a 
substantial decrease in the size of the growing follicle 
population, and by implication of the non-growing 
population, after treatment. Chemotherapy has been 
shown to affect both the stroma and vasculature of the 
human ovary, causing fibrosis and hyalinisation of small 
vessels with loss of primordial follicles within areas of 
damage.4 Changes in ovarian stromal function with age 
include fibrosis and other hallmarks of chronic 
inflammation, such as the presence of macrophages,21 and 
can impair follicle development.22 These changes could be 
reversed by gonadotropin suppression,22 indicating that 
the increases in concen trations of luteinising hormone 
and follicle-stimulating hormone during chemotherapy 
shown here could be of aetiological importance, and the 
pre-existing more fibrotic stroma in older women could be 
more susceptible to chemotherapy-induced changes than 
the stroma in younger women, even with so-called low 
gonadotoxicity regimens such as ABVD or AVD. These 
age-associated effects of chemotherapy could have 
therapeutic implications and be part of the mechanism of 
action of gonadotropin-releasing hormone agonists to 
reduce the risk of premature ovarian insufficiency after 
chemotherapy for breast cancer,23,24 although this effect has 
not been confirmed for women treated for lymphoma.25
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The effect of age on recovery of ovarian function after 
both regimens, and the different toxic effects of each 
regimen on the ovaries, is also supported by our analysis 
of follicle-stimulating hormone recovery in the whole 
RATHL study cohort. In this analysis, follicle-stimulating 
hormone was dichotomised at a value consistent with 
premature ovarian insufficiency.11 In addition to con-
firming the effect of age on recovery from treatment with 
ABVD or AVD, our analysis showed clear differences in 
both the speed and extent of recovery between regimens, 
supporting the antimüllerian hormone data. Follicle-
stimulating hormone concentrations are affected to a 
much greater extent than antimüllerian hormone 
concentrations by changes across the menstrual cycle and 
use of hormonal contraception, but our analysis shows 
measurement of follicle-stimulating hormone concen-
trations is of value in large cohorts in which more detailed 
characterisation is difficult.
Previous analyses in women with breast cancer have 
shown that receiving treatment at a young age and high 
concentrations of anti müllerian hormone before treat-
ment are predictive of recovery of ovarian function after 
chemotherapy, albeit with variable relative contri-
butions.5,9,14,15 Women with breast cancer are generally 
older (approximate mean age 40 years5,9,14,15) than those 
with Hodgkin’s lymphoma and treatment involves more 
gonadotoxic alkylating agent-based regimens, resulting 
in a high probability of premature loss of ovarian 
function, particularly in women older than 40 years. 
These differences emphasise the need for defined 
populations and treatment regimens to analyse the toxic 
effects of chemotherapeutic regimens on the ovaries and, 
particularly, recovery.
The data in this study support the paucity of the value 
of current ovarian reserve markers for the prediction of 
fertility in the short term, because very low concentrations 
of antimüllerian hormone did not preclude chances of 
pregnancy. The lack of predictive value of anti müllerian 
hormone measurements for short term fertility has been 
shown in prospective cohorts of women mostly in their 
twenties and thirties,26,27 and in women after cancer treat-
ment.28 This study was not designed to assess chances of 
pregnancy after treatment, and indeed current clinical 
advice is that women should not attempt to conceive after 
chemotherapy for around 1–2 years—ie, most of the 
duration of follow-up in this study. We do not know how 
many women in each group attempted to conceive, but a 
similar proportion of pregnancies were seen in women 
in the BEACOPP group as in the ABVD-AVD group 
within the substudy. Although these results show that a 
low concentrations of antimüllerian hormone do not 
preclude pregnancy in the short term, they probably do 
indicate a reduced interval to menopause and thus a 
shortened duration of opportunity to achieve pregnancy 
in the longer term.29 Thus, a low concentration of 
antimüllerian hormone after recovery from chemo-
therapy could identify women who should not unduly 
postpone pregnancy, and inform individualised discus-
sion; longer follow-up studies are needed to assess this 
interpretation.
Our study had several limitations. The study was not 
designed to assess fertility, which would require longer 
follow-up and a design that incorporates intention to 
conceive. The antimüllerian hormone analysis is restricted 
by the size of the dataset, reflecting the short period for 
which recruitment was open for the substudy. We also 
acknowledge the limitations of using follicle-stimulating 
hormone measurements in isolation without a more 
robust evidence of premature ovarian insufficiency, which 
was not possible in the main RATHL trial, and data on 
hormonal contraceptive use during and after treatment 
were not available.
In conclusion, the results of this secondary analysis of 
the RATHL trial indicate the value of antimüllerian 
hormone as a biomarker of toxic effects of chemotherapy 
on the ovaries during and after different chemo therapy 
regimens for advanced Hodgkin’s lymphoma. We provide 
additional evidence that treatment with ABVD or AVD has 
no detectable effect on gonadal function in young women, 
although increasing age does restrict ovarian recovery; 
confirmation in larger studies is needed to confirm and 
define this interpretation more precisely, and determine 
its mechanism. By contrast, BEACOPP shows substantial 
gonadotoxicity in women of all ages, although some 
patients might have sufficient ovarian function after 
treatment to achieve pregnancy. Concentrations of 
antimüllerian hormone after treatment could be of use in 
advising women treated for Hodgkin’s lymphoma of their 
probable reproductive lifespan after treatment.
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